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Available online 15 April 2014Abstract Background: Ovarian teratocarcinoma (OVTC) arises from germ cells and contains a high percentage of cancer
stem/progenitor cells (CSPCs), which promote cancer development through their ability to self-renew. Androgen and androgen
receptor (androgen/AR) signaling has been reported to participate in cancer stemness in some types of cancer; however, this
phenomenon has never been studied in OVTC.
Methods: Ovarian teratocarcinoma cell line PA1 was manipulated to overexpress or knockdown AR by lentiviral deliver
system. After analyzing of AR expression in PA1 cells, cell growth assay was assessed at every given time point. In order to
determine ligand effect on AR actions, luciferase assay was performed to evaluate endogenous and exogenous AR function in
PA1 cells. CD133 stem cell marker antibody was used to identify CSPCs in PA1 cells, and AR expression level in enriched CSPCs
was determined. To assess AR effects on CD133+ population progression, stem cell functional assays (side population, sphere
formation assay, CD133 expression) were used to analyze role of AR in PA1 CSPCs. In tissue specimen, immunohistochemistry
staining was used to carry out AR and CD133 staining in normal and tumor tissue.
Results: We examined androgen/AR signaling in OVTC PA1 cells, a CSPCs-rich cell line, and found that AR, but not androgen,
promoted cell growth. We also examined the effects of AR on CSPCs characteristics and found that AR expression was more
abundant in CD133+ cells, a well-defined ovarian cancer stem/progenitor marker, than in CD133− populations. Moreover,
results of the sphere formation assay revealed that AR expression was required to maintain CSPCs populations. Interestingly,Abbreviations: CSPCs, cancer stem/progenitor cells; OVTC, ovarian teratocarcinoma; AR, androgen receptor; DHT, 5α-dihydrotestosterone;
DMEM, Dulbecco's modified Eagle medium; Ct, threshold value; hrEGF, human recombinant epidermal growth factor; hrbFGF, human recombinant
basic fibroblast growth factor.
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25Ligand-independent role AR in the development of OVTCthis AR-governed self-renewal capacity of CSPCs was only observed in CD133+ cells. In addition, we found that AR-mediated
CSPCs enrichment was accompanied by down-regulation of p53 and p16. Finally, co-expression of AR and CD133 was more
abundant in OVTC lesions than in normal ovarian tissue.
Conclusion The results of this study suggest that AR itself might play a ligand-independent role in the development of OVTC.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).IntroductionOvarian tumors are classified according to the assumed cell
type of origin, namely surface epithelium (ovarian carcinoma),
stroma (ovarian adenoma), salpin (fallopian tube cancer), and
germ cells (ovarian teratoma) (Zhang et al., 2008; Koshy et al.,
2005; Wasim et al., 2009). Ovarian teratoma, a mixed germ
cell tumor, comprises approximately 20% of ovarian neoplasms
(Sviracevic et al., 2011; Oliveira et al., 2004; Moniaga and
Randall, 2011). Teratocarcinoma (OVTC), a very aggressive
ovarian tumor, accounts for approximately 10–15% of germ
cell tumor (Koshy et al., 2005; Sviracevic et al., 2011; Oliveira
et al., 2004; Moniaga and Randall, 2011); however, the
pathogenesis of this type of tumor is poorly understood. It is
well known that sex steroid hormones such as androgens,
estrogens, and progesterone play pivotal roles in reproductive
function throughout reproductive ages (Walters et al., 2008;
Ahmad and Kumar, 2011); however, little is known about their
impact on OVTC development and progression.
Cancer stem/progenitor cells (CSPCs) are thought of as a
confounding factor for carcinogenesis and cancer progression
because of their capacity for unlimited self-renewal. Studies
have shown that several glycoproteins, namely CD133 (Baba et
al., 2009; Chen et al., 2014), CD117 (Luo et al., 2011), CD24
(Gao et al., 2010), and CD44 (Meng et al., 2012), as well as the
transcription factors OCT-4 (Jiao et al., 2013) and Nanog (Lee
et al., 2012), are markers of CSPCs in ovarian tissue. PA1, an
OVTC cell line, is an excellent cell line for studying cancer
stem cell characteristics because it abundantly expresses the
CSPCs marker CD133 (Skubitz et al., 2013; Guo et al., 2011;
Chung et al., 2013). In addition to using biomarkers to
distinguish CSPCs, analysis of sphere-forming capacity is also
a reliable method for detecting and characterizing CSPCs
populations (Chung et al., 2013; Williams et al., 2010; Szotek
et al., 2006; Fong and Kakar, 2010).
Androgens play important roles in both male and female
reproductive organs (Chang et al., 2014; Fauser et al., 2011;
Matsumoto et al., 2008). The androgens act through the
androgen receptor (AR), a transcription factor that belongs to
the nuclear receptor superfamily (Ma et al., 2014). AR exerts
physiological and pathological functions in organisms by
translocating to the nucleus upon binding to androgens,
where it binds to specific DNA sequences (Wang et al., 2005,
2009; Ma et al., 2012a). However, non-classical androgen/AR
action has been documented in a variety of pathophysiological
conditions (Simoncini and Genazzani, 2003; Baron et al., 2004;
Singh et al., 2006; Bonaccorsi et al., 2006). There are two
types of non-classical androgen/AR actions: ligand-mediated
transient androgen/AR actions and ligand-independent AR
actions (Fujimoto et al., 2001; Heinlein and Chang, 2002;
Kousteni et al., 2001; Losel et al., 2003). Ligand-mediatedtransient androgen/AR actions are stimulated by its binding to
androgen, while ligand-independent AR actions are mediated
by growth factors (Culig et al., 1994), or protein kinases (Lyons
et al., 2008; Culig, 2004). However, both types of non-
classical actions are the result of the translocation of AR to the
nucleus where it acts as a DNA-binding transcription factor
that regulates target gene expression. In this study, we
examined whether androgen/AR signaling is involved in the
development of OVTC in vitro and in humans.
Materials and methods
Ovarian teratocarcinoma patient data from a single
cohort study
Specimens of ovarian teratocarcinoma (n = 7) analyzed in
this study were obtained from patients who had received the
diagnosis during the period 1987–2013 at the China Medical
University (Taichung, Taiwan). Patients were identified from
a single cohort registered in the Cancer Registry Database of
the hospital. Access to the tissue samples was approved by
the Internal Review Board of the China Medical University
Hospital (#DMR101-IRB2-276).
Cell culture
The human OVTC cell line (PA1), the human embryonic kidney
cell line (HEK293T), and the human prostate adenocarcinoma
cell line (LnCap) were cultured in Dulbecco's modified Eagle
medium (DMEM) (GIBCO, CA, USA) with 10% fetal calf serum
(FCS) (GIBCO, CA, USA) and 1% penicillin/streptomycin (GIBCO,
CA, USA). PA1 and LnCap cells were provided courtesy of
Dr. Min-Chie Hung (MD Anderson, TX, USA) and HEK293T cells
were obtained from Dr. Yuh-Pyng Shyr (Center of Molecular
Medicine, China Medical University Hospital, Taichung,
Taiwan). The cell lines were maintained at 37 °C in a
humidified atmosphere of 5% CO2.
Western blotting assay
Protein extraction and the immunoblot assay were performed
as previously described (Ma et al., 2012b). Briefly, cells were
washed with 1×PBS and resolved in RIPA buffer (100 mM Tris,
5 mM EDTA, 5% NP40; pH 8.0) with protease inhibitors (1 mM
phenyl-methyl sulphonyl fluoride, 1 μg/ml aprotinin, 1 μg/ml
leupeptin). Proteins were resolved by SDS–PAGE and then
transferred to PVDF membranes. Blocking of non-specific
binding was accomplished by adding 5% non-fat milk. After
application of primary antibodies (AR, N-20 Santa Cruz, CA,
USA; β-actin, Santa Cruz, CA, USA; p53 (FL-393), Santa Cruz,
26 W.-M. Chung et al.CA, USA; p16 (F-12) Santa Cruz, CA, USA), secondary antibodies
(1:3000, HRP-goat-anti-mouse and HRP-goat-anti-rabbit) were
applied for 1 h at room temperature. Signals were enhanced
using an ECL chemiluminescence kit (Millipore, MA, USA) and
detected by ChemiDoc™ XRS+ (Bio-Rad, CA, USA).
Transfection and infection procedure
The lentiviral production and infection procedures were carried
out as reported previously, with minor modifications (Ma et al.,
2012b; Lee et al., 2013). Briefly, cells were transfected with
the following lentivirus plasmids: psPAX2 packaging plasmid,
pMD2G envelope plasmid (Addgen, MA, USA), pWPI-vector ctrl,
and pWPI-hAR. Lentiviral plasmids carrying the GFP gene were
co-transfected with psPAX2 and pMD2G into HEK293T cells at a
ratio of 3:2:4 by lipofectamine 2000 (Invitrogen, CA, USA) as
per the manufacturer's instructions. After 6 h, the medium was
replaced with fresh DMEM/10% FBS medium and cells were
maintained at 37 °C in a humidified incubator in an atmosphere
of 5% CO2 for 48 h. Medium containing virus was collected by
centrifugation and filtered through a 0.45 μm filter. Medium
containing 0.8 mg/ml polybrene (Sigma-Aldrich, MO, USA) was
then added to culture dishes containing 106 PA1 cells. After
16 h of infection, the medium containing virus was replaced
with fresh DMEM/10% FBSmedium and cells weremaintained at
37 °C in a humidified incubator in an atmosphere of 5% CO2 for
48 h. Infected cells were then collected and analyzed. The
green fluorescence protein (GFP)+ cells were measured by
flowcytometry (BD, CA, USA, LSR II Flow Cytometry) to
determine infection efficiencies. GFP+ cells with infection
efficiencies greater than 85% were subjected to the following
experiments.
Total RNA isolation and cDNA synthesis
RNA was extracted from PA1 cells as reported previously (Ma
et al., 2012b). Briefly, cells that had reached 80–90%
confluence in 100-mm dishes were lysed with 1 ml Trizol
(Invitrogen, CA, USA). Phenol/chloroform was then added and
RNA-rich layers were separated by centrifugation. Soluble RNA
was precipitated with 2-propanol. RNA was then rinsed with
75% ethanol and then dissolved in RNase-free water. For
first-strand cDNA synthesis, 5 μg of total RNA was used to
perform reverse transcription PCR by the PrimeScript™ RT
reagent kit (TAKARA Bio Inc., Kyoto, Japan). cDNA was
synthesized according to the manufacturer's instructions.
Quantitative real-time PCR analysis
A real-time detection system (Bio-Rad Laboratories, Inc.,
CA, USA) and the KAPA™ SYBR FAST One-Step qRT-PCR Kit
(KAPABIOSYSTEMS, MA, USA) were used according to the
manufacturers' instructions. Relative gene expression was
determined by normalizing the expression level of the target
gene to the expression level of a housekeeping gene
(β-actin). Threshold value (Ct) dynamics were used (2−ΔΔCt)
for quantitation of gene expression. The qRT-PCR primer
sequences were as follows: CD133 forward 5′-TCT CTA TGT
GGT ACA GCC G-3′, reverse 5′-TGA TCC GGG TTC TTA CCT
G-3′; CD24 forward 5′-TTT ACA ACT GCC TCG ACA CAC ATA
A-3′, reverse 5′-CCC ATG TAG TTT TCT AAA GAT GGA A-3′;CD44 forward 5′-GAC CTC TGC AAG GCT TTC AA-3′, reverse
5′-TCC GAT GCT CAG AGC TTT CTC-3′; CD117 forward 5′-CAA
GGA AGG TTT CCG AAT GC-3′, reverse 5′- CCA GCA GGT CTT
CAT GAT GT-3′; Nanog forward 5′-GGG CCT GAA GAA AAC
TAT CCA TCC-3′, reverse 5′-TGC TAT TCT TCG GCC AGT TGT
TTT-3′; OCT-4 forward 5′-GGC CCG AAA GAG AAA GCG AAC
C-3′, reverse 5′-ACC CAG CAG CCT CAA AAT CCT CTC-3′; SCF
forward 5′-ACT GAC TCT GGA ATC TTT CTC AGG-3′, reverse
5′-GAT GTT TTG CCA AGT CAT TGT TGG-3′.
Cell growth analysis
The WST-1 assay (Roche, Basel, Switzerland) was used to
assess cell growth. Briefly, 103 cells/100 μl/well were seeded
in 96-well plates with DMEM in 10% charcoal-dextran treated
FBS (CDFBS) and were incubated for designated time periods
(1, 2, 4, 6, 8 days). Then, 10 μl of WST-1 solution was added to
each well and cells were allowed to incubate at 37 °C in an
incubator for an hour. Cell viability was quantified by
colorimetric detection in an ELISA plate reader (BECKMAN, Il,
USA, COULTER PARADIGM™ Detection Platform) at an absor-
bance of 450 nm and 690 nm to generate an OD proportional
to the relative abundance of live cells in the given wells.
Colony formation assay and Standard cell
number count
Two sets of 1.5 × 105 cells/dish were seeded in 6-cm plates
with DMEM in 10% CDFBS and incubated for 8 days. In one set of
cells, 1000 μl of 4% formaldehyde solution was added to fixed
cells and the cells were allowed to incubate at room
temperature for one hour. Crystal violet cell staining was
then performed. After 1 h, crystal violate was washed from the
cell culture dish and cell colonies were photographed. The
other set of cells were subjected for cell counting.
Luciferase assay
The assay was performed as previously described (Lyons et
al., 2008). Briefly, pGL3-ARE (androgen response
element-driven luciferase reporter plasmid) and pRL-TK
(thymidine kinase promoter-driven renilla luciferase plas-
mid) were transiently co-transfected into cells. After 6 h,
medium was replaced with fresh medium and 10% CDFBS.
Cells were then cultured for 48 h with or without DHT
(10 nM). After 24 h, cells were washed with 1×PBS and then
incubated in the presence of 100 μl CCLR (cell culture lysis
reagent) (Promega, WI, USA) at room temperature for
30 min. Cell lysates were then placed in a microtube and
centrifuged at 14,000 rpm for 5 min. Supernatant (5 μl) was
then mixed with 50 μl luciferase assay reagent. Luciferase
activity was measured immediately using a luminescence
microplate reader and presented as relative luminescence
units.
Side population analysis
Side population analysis was preformed as described previ-
ously by Goodell (Hirschmann-Jax et al., 2004). Briefly, 106
cells were detached and washed, and then incubated in DMEM
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Aldrich, MO, USA) for 90 min at 37 °C, either alone or in the
presence of 50 μM verapamil (Sigma-Aldrich, MO, USA). After
certain incubation time periods, cells were washed with
ice-cold 1× PBS and then resuspended with 1× PBS supple-
mented with 2% FCS and 2 μg/ml propidium iodide (Sigma-
Aldrich, MO, USA) at 4 °C for 5 min, to exclude dead cells. The
cells were analyzed using flowcytometry (BD, CA, USA, LSR II
FlowCytometry) with dualwavelength analysis (Hoechst-blue,
424–444 nm; Hoechst-red, 675 nm) after excitation with
350 nm UV light.
Verification and sorting of CD133+ cells
Cells were detached with 1% trypsin/EDTA and cell membrane
non-specific binding to antibodies was blocked by 5% BSA for
30 min at room temperature. Cells were then incubated with
antibody CD133-APC (MACS, Miltenyi Biotech, Gladbach,
Germany) for 30 min and then subjected to flowcytometry
(FACS, BD, CA, USA, FACSAria) analysis. The CD133+/− cells
were collected by a cell sorter (BD, CA, USA, FACSAria).Figure 1 AR promotes OVTC PA1 cell growth. A. Western blottin
higher in PA1 cells infected with AR cDNA (pWPI-hAR; AR) than in con
control. The graph on the right-hand side is quantitation data of A
assays were performed at the indicated time points (1, 2, 4, 6, 8 day
wave length at 450 nm deducted from that of 630 nm background re
promotes cell growth. Cell number count was analyzed and photogra
AR expression was significantly lower in PA1 cells infected with
Luciferase; siLuc). LnCap cells served as a positive control. The gra
expression. E. AR siRNA suppressed cell growth. WST-1 assays were
Y-axis indicates the absolute Abs. of siLuc and siAR infected cells
analyzed and photographed on day 8. The results shown are from 3 in
than 0.05.Sorting of CD133+ and CD133− populations
A CD133 MicroBead kit (Miltenyi Biotec, Gladbach, Germany)
was used to sort PA1 CD133+ cells according to the
manufacturer's instructions. Briefly, 108 cells were washed,
resuspended in 300 μl of buffer (1X PBS/pH 7.2, 0.5% BSA/
2 mM EDTA) with 100 μl FcR Blocking Reagent and 100 μl of
CD133 MicroBeads, mixed well, and then incubated for 30 min
at 2–8 °C. The labeled cells were then washed, resuspended
in 500 μl buffer, and then applied to a MACS Column to collect
unlabeled cells (CD133− cells). Finally, the column was
removed from the magnet and placed in collection tubes to
collect magnetically-labeled cells (CD133+ cells).Sphere formation assay
Cells were collected and washed to remove serum and then
suspended in serum-free DMEM supplemented with 20 ng/ml
human recombinant epidermal growth factor (hrEGF), 10 ng/ml
human recombinant basic fibroblast growth factor (hrbFGF),g (left-hand side) showed that AR expression was significantly
trol cells (pWPI-vector ctrl; Vec). LnCap cells served as a positive
R protein expression. B. AR cDNA promotes cell growth. WST-1
s). The Y-axis indicates the absolute light absorbance (Abs.; Abs.
adings). Vec and AR infected cells were compared. C. AR cDNA
phed on day 8. D. Western blotting (left-hand side) showed that
AR siRNA (pLKO.1-siAR; siAR) than in control cells (pLKO.1-si
ph on the right-hand side is the quantitation data of AR protein
performed at the indicated time points (1, 2, 4, 6, 8 days). The
. F. AR siRNA suppressed cell growth. Cell number count was
dependent experiments. *Indicates significance at a p-value less
Figure 2 Ligand-independent AR effects on OVTC PA1 cell
growth. A. DHT effect on growth of PA1 cells. WST-1 assay was
performed on DHT 10 nM treated PA1 cells at indicated time points
(1, 2, 4, 6, 8 days). The Y-axis indicates the absorbance (Abs.).
B. Endogenous AR transactivation activity was absent in PA1 cells.
ARE-luciferase assaywas performed in DHT 10 nM treated PA1 cells.
Thymidine kinase promoter-driven Renila construct (pRL-TK) was
co-transfected and measured as a transfection control. Relative
ARE-luciferase activity (fold to EtOH) is presented as transactivation
activity of AR. AR transactivation function in LnCap cells served as a
positive control. C. Exogenous AR transactivation was absent in PA1
cells. AR cDNA (pWPI-hAR; AR) or vector control (pWPI-vector ctrl;
Vec) was co-transfected with ARE-luciferase and pRL-TK in PA-1
cells to observe ARE-luciferase activity. The transfection was also
performed in 293T cells as a positive control. The results shown are
from 3 independent experiments. *Indicates a p-value less than
0.05.
28 W.-M. Chung et al.5 μg/ml insulin, and 0.4% BSA (Sigma, USA). The cells were
subsequently cultured in ultra low attachment 6-well plates
(Corning Inc., Corning, NY, USA) at a density of less than 5000
cells/well for 14 days. Spheres were observed under a
microscope and images were photographed under a phase
contrast fluorescence microscope (Nikon, ECLIPSE 80i).
Statistical analysis
Statistical analyses were performed using the Student's
t-test. All experiments were repeated at least three times,
and p-values less than 0.05 were considered to indicate
statistical significance.
Results
Ligand-independent AR actions promote OVTC
cell growth
In order to test whether androgen/AR signaling plays a role
in the development of OVTC, we first used a lentiviral-based
delivery system to engineer AR-knockdown PA1 cells and PA1
cells that overexpress AR. Results of Western blot analysis
showed that AR protein levels were approximately 40-fold
higher in PA1 cells that were engineered to overexpress AR
than in vector control cells (Fig. 1A). In addition, we found
that cells that overexpressed AR grew more rapidly than
vector control cells (Figs. 1B and C). In contrast, expression
of AR (Fig. 1D) and rate of growth (Figs. 1E and F) were
significantly lower in AR-knockdown PA1 cells than in non-
specific siRNA control cells.
We also tested the effects of androgen (5α-dihydrotes-
tosterone; DHT 10 nM) on PA1 cell growth. As seen in Fig. 2A,
DHT had little effect on PA1 cell growth. In order to better
understand ligand-independent AR functions, ARE (androgen
receptor response element) promoter assays were per-
formed. As shown in Fig. 2B, DHT treatment did not induce
luciferase activity in PA1 cells (Fig. 2B, 3rd vs. 4th lane) but
resulted in significant activity in LnCaP cells (Fig. 2B, 1st vs.
2nd lane). We further ectopically introduced wild type AR
cDNA into PA1 cells to observe AR transactivation function
(Fig. 2C). The result showed that luciferase activity was not
induced in pWPI-vector control cells or in pWPI-AR
transfected cells, although it resulted in marked luciferase
activity in pWPI-AR transfected 293T cells.
The data in Figs. 1 and 2 demonstrate that AR promotes
OVTC cell growth through a ligand-independent pathway.
AR promotes CSPCs characteristics
Studies have shown that CSPCs can trigger tumorigenesis and
promote cancer progression and that AR can promote the
growth of CSPCs in various cancers. We, therefore, tested
whether AR regulates CSPCs in OVTC. We performed a cell-
sorting assay to isolate PA1 cells that expressed the
glycoprotein CD133, a well-established biomarker of CSPCs
in ovarian cancer. Using a cell sorter and CD133 antibody, we
were able to distinguish between CD133− and CD133+ cell
populations (Fig. 3A). The 5% extremes of the staining signal
within the spectrum were defined as CD133+ and CD133−cells. Then we confirmed CSPCs characteristics by examining
other CSPCs marker genes (Fig. 3B). We found that the levels
of expression of CD133, CD24, OCT-4, Nanog, CD117, and
Figure 3 AR over-expressed in PA1 CD133+ cells. A. Definition of PA1 CD133+/− cells using flowcytometry. The basal
IgG-isotype-APC staining signal is presented on the left-hand side, and the CD133-APC staining signal is presented on the right-hand
side of the histogram. As indicated in P2 and P3, the 5% extremes of the staining signal within the spectrum were defined as CD133+
and CD133− cells. Negatively stained cells (P2, left-hand side 5%) and positively stained cells (P3, right-hand side 5%) were subjected
to the cell sorter for analysis. B. CSPCs marker genes were more highly expressed in CD133+ cells than in CD133− cells. CD133, CD24,
OCT-4, Nanog, CD117, and CD44 mRNA expressions were measured by quantitative real-time PCR, and the relative expressions were
calculated as 2−ΔΔCt. C. AR protein was more highly expressed in CD133+ cells than in CD133− cells. Western blotting assays (upper
panel) were performed to detect the expression of AR, and quantified data are shown in the lower panel. All data are from at least
three independent experiments. The variations are due to standard deviation, and * indicates statistical significance at p b 0.05.
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cells. We then measured AR expression and found that AR
expression was significantly higher in CD133+ cells than in
CD133− cells (Fig. 3C; 2nd vs. 3rd lane).
The data suggest that AR acts as a cancer progression
promoter in CSPCs. In order to further investigate this finding,
we performed a side population assay (Williams et al., 2010;
Szotek et al., 2006) in PA1 cells that overexpressed AR cDNA
and in AR-knockdown PA1 cells. Using verapamil, a calcium
channel blocker, to differentiate stem populations, we found
that overexpression of AR cDNA increased the side population
from 2.3% to 7% (Fig. 4A) and that AR siRNA knockdown
decreased the side population from 2.3% to 1% (Fig. 4B).
Moreover, we used flowcytometry to examine the effects of
AR on CD133 populations. As shown in Figs. 4C and D,
overexpression of AR resulted in an increase in CD133+ cells
(7.5% to 43%) and knockdown of AR by siRNA resulted in a
decrease in CD133+ cells (7.7% to 1.5%). Furthermore, we
used the sphere formation assay to confirm the role that AR
plays in CSPCs characteristics. As shown in Fig. 4E, AR cDNA
resulted in an increase in sphere number and size, while AR
siRNA had the opposite effect (Fig. 4F).Since we observed that AR promotes CSPCs enrichment,
we conducted further studies to better understand its role
in (progenitor) CSPCs and (non-progenitor) non-CSPCs. Using
a lentiviral-based gene delivery, we measured gene trans-
duction efficiencies with N95% GFP+ cells using the pWPI
GFP-carrying vector (Fig. 5A). Since the pLKO.1 vector
does not carry the GFP gene, we treated PA1 cells with
puromycin (5 μM) for 2 weeks and then selected
puromycin-resistant cells. Then we sorted out CD133+/−
cells to perform the sphere formation assay. As shown in
Fig. 5B, CD133+ cells formed larger spheres than CD133−
cells (Figs. 5B and C). Knockdown or overexpression of AR in
CD133− cells showed little effect on sphere formation;
however, knockdown of AR suppressed (Fig. 5B) and
overexpression of AR dramatically enhanced (Fig. 5C) sphere
formation in CD133+ cells.
It has been documented that regulation of p53–p21 and Rb–
p16 tumor suppression pathways are associated with cellular
senescence (Wu et al., 2011; Chen et al., 2011; Serrano et al.,
1997) and cancer stemness (Armesilla-Diaz et al., 2009; Zheng
et al., 2008; Akala et al., 2008; Strauss et al., 2012) by
controlling cell cycle. Furthermore, our previous study
Figure 4 AR enriches CSPCs populations. A. AR cDNA increased side population (SP) of PA1 cells. The SP cells were defined by
Hoechst staining with or without verapamil treatment (circled area) in pWPI-vector control (Vec) and pWPI-hAR (AR) infected PA1
cells (dot-plot graphs on the left). The percentage of SP cells is shown on the right-hand side. B. AR siRNA knockdown decreased
side-population (SP) of PA1 cells. The SP cells were defined by Hoechst staining with or without verapamil treatment (circled area) in
pLKO.1-si Luciferase (siLuc) and pLKO.1-siAR (siAR) infected PA1 cells (dot-plot graphs on the left). The percentage of SP cells is
showed on the right-hand side C. AR enhanced CD133 expression and population. Flowcytometry was performed using CD133-APC
conjugated antibody to measure Vec- and AR-infected PA1 CD133 expression (histogram on the left), and CD133 population
(right-hand side of the bar graphs). D. AR knockdown suppressed CD133 expression and population. Flowcytometry was performed to
measure siLuc- and siAR-infected PA1 CD133 expression (histogram on the left), and CD133 populations (right-hand side bar graphs).
E. AR promotes CSPCs sphere formation. Sphere images of Vec- and AR-infected PA1 cells (day-1 and day-14) were taken by a
phase-contrast microscope (100×) and are shown on the left-hand side. The quantitation of sphere numbers is shown on the
right-hand side bar graph. F. AR knockdown suppressed CSPCs sphere formation. Sphere images of siLuc- and siAR-infected PA1 cells
(day-1 and day-14) were taken by a phase-contrast microscope (100×) and are shown on the left-hand side. The quantitation of sphere
numbers is shown on the right-hand side bar graph. All experiments were from at least 3 independent experiments where * indicates
p-values less than 0.05.
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cellular carcinoma (Ma et al., 2008). Therefore, we performed
immunoblot assays to see whether this was the case in
OVTC CSPCs. As shown in Fig. 5D, we found that p53 and p16
were downregulated by AR in CD133+ cells, which might
indicate that cancer stem cell stemness is associated with
the down regulation of p53 and p16 (4th vs. 3rd lane, and
4th vs. 2nd lane). Meanwhile, this data was consisted with
previous studies that inactivation of both p53–p21 and p16–Rb
signaling pathway are involved in CSPCs progression (Chen
et al., 2011).
Taken together, the results presented in Figs. 3 to 5
demonstrate that AR promotes self-renewal of CSPCs in
CD133+ PA1 cells.Co-expression of CD133 and AR in OVTC tissue
The in vitro data show that AR promotes OVTC cell growth by
promoting self-renewal of CSPCs. We further examined the
role AR has on CD133 expression in human OVTC tissue
samples using an immunohistochemical approach. Expres-
sion levels of AR and CD133 in cancer tissue were compared
with those in normal ovarian tissue taken from the same
patient. As seen in Fig. 6, it is markedly lower expression of
AR and fewer co-expression of CD133 in normal ovarian
epithelial cells (Figs. 6A and C) compared to that in ovarian
tumor epithelial cells. Furthermore, the co-expression of AR
and CD133 were more obviously in cytoplasm than nucleus
(Figs. 6B and D). Those observations strengthen our
Figure 5 AR promotes CD133 CSPCs self-renew. A. AR cDNA infection efficiency in CD133− and CD133+ PA1 cells. The green
fluorescence protein (GFP) histograms (left-hand side) of infected or non-infected cells were measured by flowcytometry. The
quantitation of GFP populations is presented on the right-hand side. B. AR knockdown sphere images of the CD133+ and CD133− PA1
cell colonies. The sphere images at day 14 were taken by a phase contrast microscope (40×). The images of CD133− and CD133+ cells
infected with siLuc (a, c) or siAR (b, d) were presented. C. AR over expression sphere images of the CD133+ and CD133− PA1 cell
colonies. The sphere images were taken on day 14 by a phase contrast microscope (40×). The images of CD133− and CD133+ infected
with Vec (a, c) and AR cDNA (b, d) were showed. D. Protein expression of p53, and p16 in CD133+ and CD133− cells by Western
blotting. The expression of actin served as a loading control. The relative band density (fold) quantitation of Western blots images are
shown below. All data were from at least three independent experiments. The variations were from the calculation of standard
deviation and the scale bar inlet indicated 50 μm. *Indicates significance at a p-value less than 0.05.
31Ligand-independent role AR in the development of OVTChypothesis that ligand-independent AR function involved in
the disease progression.Discussion
Ligand-independent AR function in cancer growth
and CSPCs self-renewalIn this study, we have demonstrated the first in vitro
evidence that AR promotes OVTC development through a
ligand-independent pathway.The functions of AR in cancer development have mostly
been studied in prostate cancer (Heinlein and Chang, 2004).
The current therapeutic paradigm for prostate cancer is
androgen ablation therapy (Pienta and Bradley, 2006).
However, some studies have shown that ligand-independent
activation of AR is responsible for relapsed prostate cancer
after anti-androgen therapy (Culig, 2004; Taplin and Balk,
2004; Jenster, 1999, 2000). Studies in prostate cancer cells
reported that AR transactivation was mediated by growth
factors, such as IGF-I, KGF, EGF (Culig et al., 1994), and the
CXCL12/CXCR14 axis (Kasina and Macoska, 2012) in the
absence of androgen. Kasina and Mascoska's (2012)study
illustrated that intracellular signals of those growth factors
Figure 6 AR and CD133 expression in human ovarian teratocarcinoma tissues. A, B. AR expression in normal (A) and OVTC (B) tissues
of same patient (×40). C, D. Serial sections of CD133 expressions in normal (C) and OVTC (D) tissues of same patient (×40). Blue color
represents the nucleus and brown color represents AR antibody staining or CD133 antibody staining.
32 W.-M. Chung et al.i.e. Rho GTPase (Lyons et al., 2008), MAPK, or AKT pathway
(Feldman and Feldman, 2001) play a role in the ligand-
independent function of AR in prostate cancer cells. There-
fore, ligand-independent functions of AR appear to be
triggered by intracellular signaling molecules that translocate
AR into the nucleus (Culig et al., 1994; Lyons et al., 2008;
Kasina and Macoska, 2012; Feldman and Feldman, 2001). The
results of those studies imply that targeting of those signals as
well as AR would improve the effectiveness of therapy for
advanced prostate cancer. In addition, our previous work
demonstrated that AR enhanced CSPCs in specimens of
endometrial cancer associated with Cisplatin resistance
(Chen et al., 2014).
In this study, we found two interesting, yet previously
unreported phenomena: AR can exert biological functions in
OVTC cells in a ligand-independent manner and AR function
can promote cancer cell growth through a pathway that does
not involve transactivation. One possibility of this ligand-
independent AR function might be that AR acts as transcrip-
tional factor co-factor to regulate gene expressions.Pathophysiological roles of AR in OVTC
Few studies have provided evidence that androgen/AR play a
role in OVTC. Previous studies (Chadha et al., 1993; Cardillo etal., 1998; Shintaku et al., 2011) showed that 84% of benign and
malignant ovarian tumors expressed AR; yet, there is no clear
distinction between AR expression and ovarian cancers of
different cellular origins. Because of the rarity of OVTC, few
studies have been conducted on the pathogenesis of the
disease. Herein, we have demonstrated that AR promotes the
development and progression of OVTC by influencing tumor-
igenic CD133+ CSPCs populations. Furthermore, this is the
first study showing that a male hormone receptor promotes
ovarian cancer in a ligand-independent manner.p53 and p16 are involved in
ligand-independent-AR-regulated
OVTC CSPC progression
The tumor suppressor protein p53 plays a pivotal role in cell
cycle arrest, senescence, DNA repair and programmed cell
death. An abundance of evidence shows that p53 plays a
critical role in self-renewal and differentiation of various
cancer stem cells by controlling the cell cycle (Armesilla-Diaz
et al., 2009; Zheng et al., 2008; Akala et al., 2008).
Furthermore, our previous study demonstrated that AR
suppressed p53 expression in murine hepatic cells and that
loss of hepatic AR promoted p53-mediated DNA damage
sensing and repair systems as well as apoptosis (Ma et al.,
Figure 7 Illustration showing how AR promotes OVTC cell growth through CSPCs self-renewal. Ligand-independent AR function in
CSPCs cells (e.g. CD133+ cells) facilitates OVTC cell growth. The expression of AR in CSPCs cells is accompanied by down-regulation of
p53 and p16.
33Ligand-independent role AR in the development of OVTC2008). Our findings demonstrated that AR expression promotes
self-renewal of CSPCs. Studies have shown that expression of
the tumor suppressor gene p16 results in cell cycle arrest by
inhibiting CDK4 and CDK6 (Akala et al., 2008; Strauss et al.,
2012). Its downregulation was also reported to be essential for
cellular quiescence in cancer stem cells (Wu et al., 2011; Chen
et al., 2011; Armesilla-Diaz et al., 2009; Strauss et al., 2012).
Notably, the p53–p21 and p16–Rb pathways are two important
arms converging cellular senescence that attenuates tumori-
genicity while they were inactivated (Wu et al., 2011; Chen
et al., 2011; Serrano et al., 1997; Armesilla-Diaz et al., 2009;
Zheng et al., 2008; Akala et al., 2008).
In this study, we found that overexpression of AR in
CD133+ cells was associated with down-regulation of p53
and p16 (Fig. 5D). This result not only supports our previous
finding that AR plays an important role in the progression of
hepatoma (Ma et al., 2008), but also provides evidence that
CSPCs progression is mediated by ligand-independent
AR-p53/p16 signaling. Taken together, our data indicate
that AR controls OVTC CSPC progression by regulating, in a
ligand-independent manner, p53- and p16-related events,
such as cell cycle regulation.Conclusion
The present study provides evidence that expression of AR in
the absence of increased AR-mediated transcription exerts
biological functions which indicates that ligand-independent
AR function in CSPCs (e.g. CD133+ cells) facilitates OVTC
cell growth, and that the expression of AR in CSPCs is
accompanied by down-regulation of p53 and p16 (Fig. 7).
Our data not only demonstrate a novel mechanism by which
AR regulates cancer cell behavior, but also provides
pathological insights into germ cell tumors.Contribution of authors
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